Llwytho...
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by clonal proliferation of differentiated myeloid cells leading to bone marrow fibrosis, cytopenias and extramedullary hematopoiesis. In late 2019, the FDA approved the highly selective JAK2 inhibitor, fedratinib, for intermediate-2 o...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cancer Manag Res |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6935287/ https://ncbi.nlm.nih.gov/pubmed/31920387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S212559 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|